Cargando…

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia

The phosphatidyl-inositol 3 kinase (PI3K) δ inhibitor, idelalisib (IDE), is a potent inhibitor of the B-cell receptor pathway and a novel and highly effective agent for the treatment of chronic lymphocytic leukemia (CLL). We evaluated the activities of IDE in comparison to bendamusine (BEN), a commo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kost, Sara E. F., Saleh, Ali, Mejia, Edgard M., Mostafizar, Marina, Bouchard, Eric D. J., Banerji, Versha, Marshall, Aaron J., Gibson, Spencer B., Johnston, James B., Katyal, Sachin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826782/ https://www.ncbi.nlm.nih.gov/pubmed/31601046 http://dx.doi.org/10.3390/cancers11101519

Ejemplares similares

DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
por: Kost, Sara E. F., et al.
Publicado: (2023)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
por: Modi, Prexy, et al.
Publicado: (2017)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia
por: Wu, Xun, et al.
Publicado: (2021)

Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment
por: Roy Chowdhury, Subir, et al.
Publicado: (2020)

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015)

Role of bendamustine in the treatment of chronic lymphocytic leukemia
por: Jamshed, Saad, et al.
Publicado: (2009)

Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia
por: Roy Chowdhury, Subir, et al.
Publicado: (2018)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Targeting Metabolism and Autophagy in the Context of Haematologic Malignancies
por: Banerji, Versha, et al.
Publicado: (2012)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat, Yazan F, et al.
Publicado: (2016)

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia
por: Bourrier, Nicole, et al.
Publicado: (2022)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells
por: Hock, Barry D., et al.
Publicado: (2017)

Comparison of outcome of patients with CLL who are referred or nonreferred to a specialized CLL clinic: a Canadian population‐based study
por: Beiggi, Sara, et al.
Publicado: (2016)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial
por: Montillo, Marco, et al.
Publicado: (2019)

Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada
por: Lachaine, Jean, et al.
Publicado: (2023)

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells
por: Chowdhury, Subir Roy, et al.
Publicado: (2021)

Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives
por: Sriwijitalai, Won, et al.
Publicado: (2019)

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia
por: Primo, Daniel, et al.
Publicado: (2018)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
por: Zelenetz, Andrew D., et al.
Publicado: (2017)

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada
por: Lachaine, Jean, et al.
Publicado: (2021)

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
por: Robak, Tadeusz, et al.
Publicado: (2016)

BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA
por: Bogeljić Patekar, Martina, et al.
Publicado: (2018)

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
por: Ghia, Paolo, et al.
Publicado: (2020)

Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling
por: Dielschneider, R F, et al.
Publicado: (2014)

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade
por: Yang, Jiayu, et al.
Publicado: (2023)

Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment
por: Rosamilio, R., et al.
Publicado: (2016)

Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia
por: Gao, Hang, et al.
Publicado: (2020)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
por: Burke, Russell T, et al.
Publicado: (2014)

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
por: Michallet, Anne-Sophie, et al.
Publicado: (2018)

Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases
por: Eren, Rafet, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0j4sat2tprlmo36n7omvq30gt1